Merck KGaA (MKGAY) reacted to press reports and confirmed late-stage discussions with SpringWorks Therapeutics (SWTX) on a potential acquisition. The parties are in discussion on the basis of a price of around $47 per share. Merck noted that no final decision has been taken and no legally binding agreement has been entered into.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX:
- Merck KGaA near $47 per share deal to buy SpringWorks Therapeutics, WSJ says
- SpringWorks EU approval would enhance strategic value, says Evercore
- Positive opinion for Ogsiveo would de-risk SpringWorks deal, says Barclays
- SpringWorks Therapeutics price target lowered to $84 from $87 at BofA
- Merck KGaA says ‘no certainty’ SpringWorks deal will be signed